 |
| |
 R&D Innovation & Strategies –Integrated Strategies To Over Come Pitfalls, Enhance Drug Discovery, Overcome Attrition & New Prediction Tools That Drive Clear Decision Making.
Focused Sirna Screens In Disease Based Assays - The Fast Track To A Target
Non-Invasive, Label-Free Assays - Getting the Most Out of your Targets and a Handle on Off-Target Effects
In Silico Innovation To Solve Drug Discovery – In-Silico Data, Data Mining, Predictive Modeling,
Partnerships, Alliances & Outsourcing –Successful Partnerships, Managing Alliances, Balancing Conflicting Interests, Biotech Technology Platforms
Exploring the impact & success rate of HTS Compound Library Screening.
Intergration of technologies & applications to bridge the gap between discovery, validation & development
How do you create intelligence from all this data, both structured and unstructured, across the entire value chain?
Streamline data processes and integration whilst improving early decision making and lowering attrition through the benefit of developing a dynamic workflows and an efficient infrastructure.
“An innovative approach”-lean/ 6-sigma efforts and organisational structures supporting lead optimisation."
Alternative cost effective screening methods and techniques to strengthen assay effectively. Bringing in-vitro screening for HTS, hit optimisation & lead optimisation together.
|
|
|
 |
|
| |
| |
Examine and analyise the value & impact of biomarkers, in particular within the role of translational and personalised
medicine, Q&A sessions on what is the role of validated biomarker and the impact of imaging and toxicology within
this ever evoloving R&D envoiroment. |
|
| |
Dr. PAUL DOMANICO,
Former Vice President
Technology |
|
|
DR LUTZ JERMUTUS,
Senior Director Technology, |
|
|
PROF JURGEN BORLAK
Director Toxicology Fraunhofer Institute |
| |
|
|
MICHAEL R. HANLEY, PH.D.
Chief Scientific Officer Amylin Pharmaceuticals |
|
|
|
| |
TRANSLATIONAL MEDICINE & BIOMARKERS |
|
|
| |
Examine how non-invasive imaging can improve R&D productivity.
Learn about the role of radiotracers & contrast- agents for the visualization of targets, organs & processes. Develop a consistent imaging protocol & determine a single set of biomarkers by using technology that translate from pre-clinical to clinical. real examples of non-invasive imaging applications for oncology, cns, arthritis, cardiology & early toxicity studies.Director of Drug Discovery MRC Technology
|
|
| |
Create a platform for innovation: cell based assay technology,
Comprehensive solutions and support that complement sophisticated processes, “Examining Robust Assay Development Strategies to Meet Requirements for Functional Screens ” |
|
| |
Techniques-combining imaging biomarkers
highlighting the benefits of multiple imaging biomarkers evaluation.” Potential causes of failure when using a single imaging biomarker. |
|
| |
Biomarker Discovery and Validation strategies:
Accelerating discovery & validation through Genomics, Protein, Metabolic biomarkers as well as application of biomarker technologies in different therapeutic areas such as Oncology, CNS, techniques. |
|
|
TARGET DISCOVERY AND
VALIDATION
MANY COMPANIES ARE DEVELOPING
DRUGS AND BIOLOGICS AIMED AT A
SMALL SET OF VALIDATED DISEASERELEVANT
TARGETS. CLASSICAL
GENOMICS GENERATED A POT OF
PROMISING NEW TARGETS, HOWEVER
MANY OF WHICH CAN NOT BE VALIDATED.
SESSIONS COVERED
1. TARGET DISCOVERY THROUGH GENOMICS
2. PROTEOMIC APPLICATIONS FOR TARGET DISCOVERY
3. TARGET VALIDATION USING SARAN, HIGH CONTENT AND IMAGING TECHNIQUES, AND TOOL OR REFERENCE COMPOUNDS
4. BIOMARKERS IN DISEASE RESEARCH THAT GIVE AN EARLY INDICATION OF EFFICACY ONE & TWO |
|
|
|
|
|
|
|
|
